(188 days)
The Family of Radiofrequency System (Biorevital RF MED, ThermiSmooth 250) device is intended to provide heating for the purpose of elevating tissue temperature for selected medical conditions such as temporary relief of pain, muscle spasms, and increase in local circulation.
The Family of Radiofrequency System (Biorevital RF MED, ThermiSmooth 250) massage device is intended to provide a temporary reduction in the appearance of cellulite.
The Family of Radiofrequency System (Biorevital RF MED, ThermiSmooth 250) is a medical electrical equipment for the development of localized heat that can heat the subcutaneous tissue with radio frequency. Its particular emission frequency of 470 kHz ± 10%, the ability to regulate and control the increase of the desired temperature allows to operate with a maximum temperature of 45 ° C, and never exceed 47 °C (for safety). The electrodes dimensions included, allow to obtain a controlled heating.
The provided document is a 510(k) Premarket Notification for a Family of Radiofrequency System (Biorevital RF MED, ThermiSmooth 250). It focuses on demonstrating substantial equivalence to predicate devices for its intended uses. The document does not contain the detailed acceptance criteria and a study proving the device meets those criteria in the typical clinical performance sense that would be described for an AI/ML device.
However, based on the information provided, I can extract what is available regarding performance testing and what might be considered "acceptance criteria" in this context.
Here's a breakdown of the requested information, with the understanding that not all points are directly addressed for a "device performance" in the way one might expect for an AI/ML diagnostic:
1. Table of Acceptance Criteria and Reported Device Performance
Given the nature of the device (radiofrequency system for heating tissue), the "acceptance criteria" discussed are primarily related to electrical safety, electromagnetic compatibility, and temperature control, rather than performance metrics like sensitivity or specificity for an AI-powered diagnostic.
| Acceptance Criterion (Implicit/Explicit) | Reported Device Performance |
|---|---|
| Compliance with EN 60601-1 (Medical electrical equipment: General requirements for basic safety and essential performance) | Device "has been tested and is in compliance with EN 60601-1, Medical electrical equipment. Part 1: General requirements for basic safety and essential performance 2006/A11:2010/A1:2013." |
| Compliance with EN 60601-1-2 (Medical electrical equipment: Electromagnetic Compatibility - Requirements and tests) | Device "has been tested and is in compliance with ... EN60601-1-2 Medical electrical equipment. Part1: General requirements for safety - Collateral standard: Electromagnetic Compatibility -Requirements and tests. 2007." |
| Compliance with EN 60601-2-2 (Medical electrical equipment: Particular requirements for the safety of high frequency surgical equipment) | Device "has been tested and is in compliance with ... EN 60601-2-2 Medical electrical equipment. Part 2-2: Particular requirements for the safety of high frequency surgical equipment. 2009." |
| Software Verification (compliance with FDA regulations, standards, guidance) | "software verification was conducted to FDA regulations, standards and guidance document requirements. The results of this testing conclude the software has met these requirements." |
| Design Verification (compliance with internal design control procedures) | "Design verification was also performed on the Family of Radiofrequency System (Biorevital RF MED, ThermiSmooth 250) in compliance with internal design control procedures. The results of this testing concludes the Family of Radiofrequency System (Biorevital RF MED, ThermiSmooth 250) is determined to be safe and effective and is substantially equivalent to the predicate devices." |
| Ability to heat skin to 40-45 degrees C and maintain temperature for 10 minutes (Clinical Performance Protocol) | "Clinical Performance Protocol was performed to support use of the medical device, in particular the tests demonstrate that the device can heat the skin to 40-45 degrees C and can maintain the skin temperature inside that interval for 10 minutes similar to a heating lamp." The device itself states it operates with a maximum temperature of 45°C and never exceeds 47°C (for safety). |
2. Sample Size Used for the Test Set and Data Provenance
The document does not specify a "test set" in the context of clinical images or patient data for an AI/ML device. The "Clinical Performance Protocol" mentioned focuses on the device's ability to heat tissue.
- Sample Size: Not explicitly stated for the clinical performance protocol.
- Data Provenance: Not specified, but the device manufacturer is located in Italy (Vimodrone, Milan). "Similar to a heating lamp" suggests a basic physiological response, not complex disease assessment in a specific patient population.
- Retrospective/Prospective: Not specified, but the limited description suggests a controlled, prospective technical test rather than a large-scale clinical study on patients.
3. Number of Experts Used to Establish Ground Truth for the Test Set and Their Qualifications
Not applicable. The "ground truth" for this device appears to be the physical heating capabilities and temperature control, verifiable through instrumentation, rather than expert interpretation of medical images or conditions.
4. Adjudication Method for the Test Set
Not applicable. The clinical performance testing described is objective measurement of temperature and heating, not subjective interpretation requiring adjudication.
5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study
No. This type of study is typically performed for diagnostic devices where human readers interpret medical data (e.g., images) with and without AI assistance. This document is for a therapeutic/electrosurgical device.
6. Standalone (Algorithm Only Without Human-in-the-Loop Performance) Study
No. While software verification was done, the entire device (ThermiSmooth 250) is a physical radiofrequency system, not a standalone algorithm. Its performance is tied to its physical operation and interaction with tissue.
7. Type of Ground Truth Used
- Clinical Performance Protocol: Objective measurement of tissue temperature, and duration of temperature maintenance.
- Safety and EMC: Compliance with international standards (EN 60601 series), which is verified through specific test methods outlined in those standards.
- Software Verification: Compliance with FDA regulations, standards, and guidance for software quality.
- Design Verification: Compliance with internal design control procedures.
8. Sample Size for the Training Set
Not applicable. This is not an AI/ML device that requires a training set in the conventional sense. The device's operation is based on established radiofrequency physics and engineering, not pattern recognition learned from data.
9. How the Ground Truth for the Training Set Was Established
Not applicable, as there is no training set for an AI/ML algorithm.
{0}------------------------------------------------
Image /page/0/Picture/1 description: The image is a black and white logo for the U.S. Department of Health & Human Services. The logo features a stylized image of an eagle with three human profiles incorporated into its design. The words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" are arranged in a circular pattern around the eagle.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
Bios S.R.L. Riccardo Pisati Regulatory Affairs Via Guido Rossa, 10/12 Vimodrone I-20090 Milan, Italy
November 19, 2015
Re: K151296
Trade/Device Name: Family of Radiofrequency System (Biorevital RF MED, ThermiSmooth 250) Regulation Number: 21 CFR 878.4400 Regulation Name: Electrosurgical cutting and coagulation device and accessories Regulatory Class: Class II Product Code: PBX Dated: May 13, 2015 Received: May 15, 2015
Dear Mr. Pisati,
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21
{1}------------------------------------------------
CFR Part 807); labeling (21 CFR Part 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours.
Joshua C. Nipper -S
For
Binita S. Ashar, M.D., M.B.A., F.A.C.S. Director Division of Surgical Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration
Indications for Use
510(k) Number (if known) not assigned K151296
Device Name
Family of Radiofrequency System (Biorevital RF MED, ThermiSmooth 250)
Indications for Use (Describe)
The Family of Radiofrequency System (Biorevital RF MED, ThermiSmooth 250) device is intended to provide heating for the purpose of elevating tissue temperature for selected medical conditions such as temporary relief of pain, muscle spasms, and increase in local circulation.
The Family of Radiofrequency System (Biorevital RF MED, ThermiSmooth 250) massage device is intended to provide a temporary reduction in the appearance of cellulite.
| Type of Use (Select one or both, as applicable) | |
|---|---|
| ------------------------------------------------- | -- |
X Prescription Use (Part 21 CFR 801 Subpart D)
] Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW *
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
{3}------------------------------------------------
Section 5 510(k) Summary
Contact Details
| 510(K) Number | K151296 |
|---|---|
| Applicant Information | Bios s.r.l.Via Guido Rossa, 10/1220090 Vimodrone (MI) – Italy |
| Contact | Ing. Aldo Casalino |
| Date Prepared | 13 May 2015 |
| Device Name(s): | Family of Radiofrequency System (Biorevital RF MED, ThermiSmooth 250) |
| Trade Name | Family of Radiofrequency System |
| Common Name | Radiofrequency System |
| Classification | II |
| Classification Name | Electrosurgical, cutting and coagulation and accessories 21CFR 878.4400 |
| Product Code | PBX |
Legally Marketed Predicate Device (s)
| 510(k) Number | Pro Code | Trade Name | Applicant |
|---|---|---|---|
| K133739 | PBX 21 CFR 878.4400 | TruSculpt | Cutera, Incorporated |
| K132949 | PBX 21 CFR 878.4400 | Pellefirm System | Ellman International,Inc |
Device Description
The Family of Radiofrequency System (Biorevital RF MED, ThermiSmooth 250) is a medical electrical equipment for the development of localized heat that can heat the subcutaneous tissue with radio frequency. Its particular emission frequency of 470 kHz ± 10%, the ability to regulate and control the increase of the desired temperature allows to operate with a maximum temperature of 45 ° C, and never exceed 47 °C (for safety). The electrodes dimensions included, allow to obtain a controlled heating.
{4}------------------------------------------------
Indication for Use
The Family of Radiofrequency System (Biorevital RF MED, ThermiSmooth 250) device is intended to provide heating for the purpose of elevating tissue temperature for selected medical conditions such as temporary relief of pain, muscle spasms, and increase in local circulation.
The Family of Radiofrequency System (Biorevital RF MED, ThermiSmooth 250) massage device is intended to provide a temporary reduction in the appearance of cellulite.
Substantial Equivalence
The product specification, functionality, indication for use, and treatment parameters of the Family of Radiofrequency System (Biorevital RF MED, ThermiSmooth 250) are the same or very similar to the legally marketed, claimed predicate devices for the purpose of this 510(k) submission.
Technological differences between the Family of Radiofrequency System (Biorevital RF MED, ThermiSmooth 250) and the predicate devices are limited to small variations in the maximum power (250 W, while predicate devices have a range from 120 W to 300 W), display (touchscreen, while one predicate device uses an analogic system) and temperature control (one predicate device does not have it).
Performance Testing
The Family of Radiofrequency System (Biorevital RF MED, ThermiSmooth 250) has been tested and is in compliance with EN 60601-1, Medical electrical equipment. Part 1: General requirements for basic safety and essential performance 2006/A11:2010/A1:2013, EN60601-1-2 Medical electrical equipment. Part1: General requirements for safety - Collateral standard: Electromagnetic Compatibility -Requirements and tests. 2007 and EN 60601-2-2 Medical electrical equipment. Part 2-2: Particular requirements for the safety of high frequency surgical equipment. 2009.
In addition to the electrical safety testing performed, software verification was conducted to FDA regulations, standards and guidance document requirements. The results of this testing conclude the software has met these requirements. Design verification was also performed on the Family of Radiofrequency System (Biorevital RF MED, ThermiSmooth 250) in compliance with internal design control procedures. The results of this testing concludes the Family of Radiofrequency System (Biorevital RF MED, ThermiSmooth 250) is determined to be safe and effective and is substantially equivalent to the predicate devices.
{5}------------------------------------------------
| 510(k) Premarket Notification | Bios s.r.l. |
|---|---|
| Family of Radiofrequency System (Biorevital RF MED, ThermiSmooth 250) | rev.03 |
| Section V | pag. 3 of 3 |
Clinical Performance Protocol was performed to support use of the medical device, in particular the tests demonstrate that the device can heat the skin to 40-45 degrees C and can maintain the skin temperature inside that interval for 10 minutes similar to a heating lamp.
§ 878.4400 Electrosurgical cutting and coagulation device and accessories.
(a)
Identification. An electrosurgical cutting and coagulation device and accessories is a device intended to remove tissue and control bleeding by use of high-frequency electrical current.(b)
Classification. Class II.